Amphastar Pharma (AMPH) Tops Q4 EPS by 7c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million, versus $54.9 million reported last year.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c